Peer-Reviewed Publication
J Natl Cancer Inst2026September 24, 2026Journal Article
Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702.
George Q Zhang1,2, Chao Ma2, Victor B Yang1, Qian Shi3, Jonathan A Nowak4,2, Levi Pederson3, Tyler Twombly4, Juha P Väyrynen5, Melissa Zhao4, Yasutoshi Takashima2, Ardaman Shergill6, Pankaj Kumar7, Felix Couture8, J Philip Kuebler9, Smitha Krishnamurthi10, Benjamin Tan11, Eileen M O'Reilly12, Shuji Ogino4,13,14,15, Joel E Goldberg1, Justin C Brown16, Adham Jurdi17, Anthony F Shields18, Jeffrey A Meyerhardt2
1Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
3Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
4Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
5Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
6Department of Medicine, Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA.
7Heartland Cancer Research, National Cancer Institute Community Oncology Research Program, Illinois CancerCare, Peoria, IL, USA.
8Hôtel-Dieu de Québec, Québec City, QC, Canada.
9Columbus National Cancer Institute Community Oncology Research Program, Columbus, OH, USA.
10Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH, USA.
11Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
12Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY, USA.
13Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
14Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
15Institute of Science Tokyo, Tokyo, Japan.
16AdventHealth Research Institute, AdventHealth, Orlando, FL, USA.
17Natera, Inc, Austin, TX, USA.
18Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Abstract
BACKGROUND: Postoperative circulating tumor DNA (ctDNA) is a highly prognostic marker of residual disease among patients with stage III colon cancer, and physical activity has been associated with improved survival after curative resection. Whether physical activity predicts outcomes according to postoperative ctDNA status remains unknown.
METHODS: We conducted a post hoc analysis of CALGB/SWOG 8…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans